She was a biological researcher with more than 20 years of experience in both industry and academics. she had hands-on experience in high throughput screening, assay development, tumor biology, cancer immunology, neuroimmunology, IND filing and early phase clinical trial, etc. For the drug development, she has been involved in both small molecules and biological drugs like bispecific T cell engager and bispecific ADC. The disease area relating to my drug development includes anti-viral, anti-cancer, auto-immune, etc. She has extensive experience in target validation, preclinical PD, PK, toxicity, and MOA studies for the pipelines. In addition, she had accumulated rich experience in basic and translational research in tumor biology and tumor immunology in academic before joining the company. After moving back and forth between industry and academic, She gained deeper and deeper understanding about the relationship of the unmet clinic need and the advantages and uniqueness of drugs in different formats, such as biological drugs, small molecule drugs and biological-small molecule conjugates (eg, ADC , PDC), etc.